2017 American Transplant Congress
An Investigation of Biopsy-Proven De Novo Autoimmune Hepatitis After Hepatitis C Clearance with Direct Acting Antivirals in Liver Transplant Patients.
Department of Abdominal Transplantation, Baylor College of Medicine, Houston, TX
Direct acting antivirals (DAAs) for hepatitis C virus (HCV) have been widely prescribed to post-liver transplant patients for HCV clearance and are believed to be…2017 American Transplant Congress
Shared Decision Aid to Decipher Long-Term Treatment Risks for End Stage Renal Disease Patients.
Kidney transplantation is the preferred treatment for end stage renal disease (ESRD) compared to dialysis. The incidence of ESRD continues to increase while the gap…2017 American Transplant Congress
The Impact of Tacrolimus and MPA Derivative Immunosuppression on Acheived GFR in Recipients without Rejection: A Comparison of GFR of Living Donor Recipient Pairs at Six Months Post-Transplant.
Medicine, Division of Nephrology, Sacred Heart Hospital, Pensacola, FL
Analysis of the difference in estimated GFR (eGFR) of living donor recipient pairs at six months post-transplant showed that increased use of tacrolimus and MPA…2017 American Transplant Congress
Biomarkers of Epithelial-Mesenchymal Transition (EMT) in Chronic Allograft Nephropathy: Potential for Early Detection and Development of Novel Therapeutic Agents.
Pathology, BioChemistry and Medical Laboratory Sciences, Rush University Medical Center, Chicago, IL
Purpose: To detect markers and novel treatment targets related to fibrogenesis and eventual graft loss by focusing on Epithelial Mesenchymal transition (EMT) which requires understanding…2017 American Transplant Congress
Even Non-Donor-Specific HLA-Antibodies Are Associated with a Progressive Decline in Kidney Transplant Function.
University Spital Zuerich, Zuerich, Switzerland
Donor-specific anti-HLA-Antibodies (DSA) have been shown to be associated with antibody-mediated rejection episodes and a poorer long-term kidney graft function. The impact of anti-HLA-antibodies without…2017 American Transplant Congress
Kidney Waitlist Management: The Readiness Model of Predicting Transplants Under the Kidney Allocation System.
Transplant Center, Massachusetts General Hospital, Boston, MA
Based on the Organ Procurement and Transplantation Network data, between 2001 and 2016 the national kidney wait-list has grown from 51,271 to 100,791 (97%). At…2017 American Transplant Congress
It's Never too Early to Test: Frequent Anti-A2 Titer Monitoring in Blood Group B Patients is Necessary.
Medstar Georgetown Transplant Institute, Washington, DC
Introduction:With the implementation of the new Kidney Allocation System (KAS), deceased donor transplants from blood group A2 donors can now be implanted into blood group…2017 American Transplant Congress
Tacrolimus Appears to Be a Protective Factor for De Novo DSA Formation in Non-Sensitized Kidney Transplant Patients.
Background.Development of de novo donor specific antibodies (dnDSA) concerns about 10% of patients within the first year following kidney transplantation and reach about 20% within…2017 American Transplant Congress
Contribution of New Generation Sequencing to CMV Resistance Analysis in Renal Transplant Recipients (on Behalf of the CMV Resist Group).
Results from the French Cohorts 2006-2010 and OrphaVic (NCTNCT02067169) indicates that fifty percent of graft failures in renal recipients infected by HCMV after treatment with…2017 American Transplant Congress
mTOR Inhibition Diminishes Peripheral Blood CD8+CD28–CD38hi Effector/Memory T Cells and Facilitates Resolution of Belatacept-Refractory Kidney Rejection.
Belatacept, a CD28-CD80/86 blocker, was approved by the FDA to provide immunosuppression without nephrotoxicity or cardiovascular and metabolic adverse effects. As part of our multi-center…
- « Previous Page
- 1
- …
- 100
- 101
- 102
- 103
- 104
- …
- 181
- Next Page »